Current Concepts in the Management of Idiopathic Generalized Epilepsies

Chaturbhuj Rathore, Kajal Y Patel¹, Parthasarthy Salishchandra²

Department of Neurology, Smt. B. K. Shah Medical Institute and Research Center, Sumandeep Vidyapeeth, Vadodara, Gujarat, ¹Department of Critical Care, Sterling Hospital, Vadodara, Gujarat, ²Advisor & Senior Consultant in Neurology, Apollo Institute of Neurosciences, Jayanagar, Bangalore, India

Abstract

Idiopathic generalized epilepsies (IGEs) are a group of epilepsies characterized by an underlying genetic predisposition and a good response to antiseizure medicines (ASMs) in the majority of the patients. Of the various broad-spectrum ASMs, valproate is the most effective medicine for the control of seizures in IGEs. However, with the availability of many newer ASMs and evidence showing the high teratogenic potential of valproate, the choice of ASMs for IGEs has become increasingly difficult, especially in women of the child-bearing age group. In this article, we review the current evidence regarding the efficacy and safety of various ASMs in patients with IGEs and provide practical guidelines for choosing appropriate ASMs in various subgroups of patients with IGEs.

Keywords: Idiopathic generalized epilepsy, juvenile myoclonic epilepsy, levetiracetam, valproate

Introduction

Idiopathic generalized epilepsies (IGEs) are a group of epilepsies with a strong underlying genetic predisposition.¹,² IGEs make up one-fourth of all epilepsies and usually have onset at a young age. Seizures in the majority of the patients with IGEs are easily controlled but many of these patients require long-term, often lifelong, treatment. This makes the choice of antiseizure medicines (ASMs) in patients with IGEs particularly challenging as one needs to avoid long-term medicine-related side effects while maintaining effective seizure control. With the better delineation of the natural history of various IGE syndromes, availability of many newer ASMs, the discovery of newer facets to many older ASMs, and the new evidence regarding the differential effectiveness of various ASMs, the management of IGEs has undergone a significant change over the last few years. In this article, we review the current evidence for the management of various IGEs and suggest an overall approach for the management of IGEs.

Nomenclature and General Features of IGEs

In 2017, the International League Against Epilepsy (ILAE) proposed the term “genetic generalized epilepsies (GGEs)” to describe all types of generalized epilepsies with a presumed genetic basis.¹,² It also suggested that the older term IGEs should only be used to describe four well-established syndromes, namely childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and generalized tonic–clonic seizures alone (GTCA).³ Subsequently, the Nosoloy Task Force of ILAE recognized that the group of GGEs is broad and IGEs can be recognized as a distinct subgroup of GGEs.³ The GGEs group also includes certain rare syndromes such as eyelid myoclonia with absences and myoclonic absence epilepsy, which have different clinical features and prognosis.³,⁴ The present review is focused on the four IGE syndromes only.

IGEs have four types of seizures, either alone or in various combinations: Generalized tonic–clonic seizures (GTCS), absence seizures, myoclonic seizures, and myoclonic-tonic–clonic seizures. These epilepsies are classified by the predominant seizure type, age at onset, and to a certain extent by electroencephalogram (EEG) features [Table 1]. Seizures in patients with IGEs typically begin at an early age and are easy to control. While absences and myoclonic seizures can be quite frequent in untreated patients, GTCS are typically infrequent. Patients with IGEs have normal cognition, normal MRI, and no neurological deficits. EEG is usually abnormal in untreated patients and typically shows generalized, symmetrical, bisynchronous spike and wave discharges. However, a normal EEG does not exclude the diagnosis of IGEs in an otherwise typical clinical setting. The yield of EEG can be increased by
obtaining a sleep-deprived EEG, a sleep EEG, and prolonged recordings. Diagnosis of IGEs is based on the typical seizure semiology, classical EEG features, and positive family history in selected patients. Many patients with GTCA have no other seizure types and have normal EEG which makes it difficult to confirm the diagnosis in such cases. It is important to inquire about the minor seizures such as absences and myoclonic jerks in all the patients with apparent GTCS as the wrong diagnosis is often the cause for the uncontrolled seizures in patients with IGEs.

**Problem of Evidence in IGE Treatment**

The majority of the evidence for the use of ASMs in the treatment of IGEs comes from personal experiences, uncontrolled case series, and unblinded randomized controlled trials. There are no class I or class II studies evaluating the efficacy of ASMs in patients with IGEs except in CAE.[5–7] For regulatory purposes, a monotherapy indication for a particular ASM is granted only if it is shown to be superior to another treatment, either placebo or an active medicine, in a randomized controlled trial.[8] Conducting a placebo-controlled monotherapy trial in patients with epilepsy is considered unethical while there is overall reluctance to conduct double-blind active control trials.[5–8] As a rule, new ASMs are compared with a placebo in patients with uncontrolled focal epilepsies before being approved. As IGEs are much less common compared to focal epilepsies and the majority of the patients with IGEs are well controlled, it is difficult to enroll patients with IGEs in clinical trials. Secondly, drug trials typically include patients with generalized seizures which makes it likely that many patients with focal epilepsy and only generalized seizures will be included in the IGE arm. Hence, it is difficult to have patients with pure IGEs in large clinical trials. Lastly, the majority of the patients with IGEs have multiple seizure types while the primary outcomes in drug trials are restricted to one of the seizure types. Hence, it becomes difficult to evaluate the efficacy of one particular ASM for different seizure types. Despite these limitations, many pragmatic clinical trials have been undertaken in recent years in patients with IGEs that have helped in guiding the management of these patients.

**Common Principles in the Management of IGEs**

While the overall principles of management in patients with IGEs are similar to other epilepsies, certain treatment protocols are specific to IGEs.[9,10] As the majority of the patients with IGEs have multiple seizures types, the chosen ASM should be effective for all types of seizures. Importantly, certain drugs especially those acting through sodium channel blockade can aggravate seizures in patients with IGEs [Table 2].[11–13] These narrow-spectrum drugs, notably carbamazepine and phenytoin, can lead to worsening of seizure control in IGEs and are not recommended in these patients. Based on these observations, patients with IGEs or those with unclassified epilepsy are usually treated with broad-spectrum ASMs [Table 3]. Seizures in the majority of the patients with IGEs can be controlled with small doses of appropriate ASMs and hence these patients should be initiated at low doses. Lastly, the majority of the patients with IGEs, except CAE, require long-term treatment. Hence, proper choice of an ASM and patient counseling is essential to avoid long-term side effects and to ensure compliance.

### Table 1: General features of idiopathic generalized epilepsies

| Feature |
|---------|
| Have underlying genetic predisposition |
| Onset in early age, usually during childhood or adolescent age |
| Infrequent generalized seizures |
| Have absence, myoclonic, generalized tonic-clonic, and myoclonic-tonic-clonic seizures either in isolation or in various combinations |
| Early morning seizure occurrence and evidence of photosensitivity in many patients |
| Normal IQ and neurological examination |
| EEG shows bilateral, symmetrical, and synchronous generalized spike-wave discharges |
| EEG discharges are often precipitated by hyperventilation, photic stimulation, and eye closure |
| Good response to antiseizure medicines in 80–90% of the patients |

### Table 2: Drugs that can worsen specific seizure types in patients with IGEs

| Antiseizure medicine | Seizure type that can worsen | Can precipitate absence/myoclonic status epilepticus |
|----------------------|-----------------------------|---------------------------------------------------|
| Carbamazepine        | Absence, myoclonus          | Yes                                              |
| Phenytoin            | Absence, myoclonus          | Yes                                              |
| Ethosuximide*        | GTCS                        | No                                               |
| Phenobarbitone*      | Absence                     | No                                               |
| Clonazepam/Clobazam* | Absence                     | No                                               |
| Gabapentin           | Myoclonus, absence          | No                                               |
| Vigabatrin           | Myoclonus, absence          | Yes                                              |
| Tiagabine            | Myoclonus, absence          | Yes                                              |
| Lamotrigine          | Myoclonus                   | No                                               |
| Levetiracetam*       | Absence                     | No                                               |

*Probable related to ineffectiveness of ethosuximide against generalized tonic-clonic seizures. *Single case reports; not replicated. GTCS: Generalized tonic-clonic seizure

### Table 3: Drugs useful and to be avoided in patients with IGEs

| Broad-spectrum ASMs useful in IGEs | Narrow-spectrum ASMs to be avoided in IGEs |
|------------------------------------|-------------------------------------------|
| Valproate                          | Carbamazepine                             |
| Lamotrigine (can worsen myoclonus) | Oxcarbazepine                             |
| Levetiracetam/Brivaracetam         | Phenytoin                                 |
| Topiramate                         | Gabapentin/Pregabalin                     |
| Zonisamide                         | Vigabatrin                                |
| Clozabam                           |                                           |
| Perampanel                         |                                           |
| Phenobarbitone                     |                                           |

ASMs: antiseizure medicines; IGEs: idiopathic generalized epilepsies
Current Evidence for ASM Use in IGEs

As discussed above, no single ASM has class I or class II evidence of efficacy as initial monotherapy in patients with IGEs. The majority of the trials have included patients with IGEs without specifying the syndromes. Only a few studies have specifically studied the effectiveness of ASM in specific IGE syndromes.

ASMs in patients with IGEs

Many early observational studies in patients with IGEs established the efficacy of valproate in the management of these patients. With the realization that phenytoin and carbamazepine can aggravate myoclonic and absence seizures, valproate was considered as the drug of choice in patients with IGEs. After the availability of newer ASMs, many studies have reported the comparative efficacy of various ASMs in the treatment of IGEs. A large observational study, involving 962 patients with IGEs, reported 1-year seizure freedom in 54% of the patients. In this study, valproate was more effective (52%) as compared to topiramate (35%) and lamotrigine (17%). None of the patients in whom valproate was ineffective became seizure free with any other monotherapy. Of these patients with valproate-resistant seizures, 12% became seizure free with valproate and lamotrigine combination.

Subsequently, three major randomized trials have specifically examined the efficacy of various broad-spectrum ASMs in patients with IGEs. These trials have included patients with generalized seizures irrespective of the underlying syndrome. These randomized trials had a pragmatic open-label design wherein treating physicians decided the doses and treatment responses. Standard and New Antiepileptic Drugs (SANAD) trial was the first randomized nonblinded trial that recruited patients from outpatient clinics in the United Kingdom. Arm B of the trial randomized 716 patients with newly diagnosed generalized or unclassifiable epilepsy to receive valproate, lamotrigine, or topiramate. In the IGE subgroup, valproate was significantly better than the other two drugs. Overall, the results of this trial showed that valproate has better efficacy than lamotrigine and is better tolerated than topiramate. Based on these results, the authors suggested that valproate should remain the drug of the first choice for many patients with generalized and unclassified epilepsies. However, the authors also cautioned the use of valproate in women of child-bearing age due to its known side effect of teratogenicity. Subsequently, National Institute for Health and Care Excellence and Scottish Intercollegiate Guidelines Network guidelines recommended valproate and lamotrigine as initial choice ASMs for patients with newly diagnosed generalized epilepsy. With the availability of levetiracetam, subsequent trials compared levetiracetam against valproate. The Keppra (Levetiracetam) versus Older Monotherapy in Epilepsy Trial was a randomized, unblinded, pragmatic trial designed to show the superiority of levetiracetam to carbamazepine in patients with focal epilepsy and valproate in patients with generalized epilepsy. In this trial, 1688 patients were randomized to levetiracetam (n = 841) or standard ASMs (n = 847; valproate: 347; carbamazepine: 500). In this study, there was no significant difference between levetiracetam and standard ASMs for the primary outcome of time-to-treatment withdrawal. On the other hand, the time to first seizure, which indicates efficacy, was better with standard drugs. However, the trial did not achieve its estimated sample size and failed to show the superiority of levetiracetam over standard drugs. Recently, results from the SANAD II trial (Arm B; Generalized epilepsy) have shown that valproate is superior to levetiracetam in patients with generalized epilepsies. In the per-protocol analysis, valproate was found to be superior as compared to levetiracetam for 12-month remission. Valproate was also found to be superior for the outcome of time-to-treatment failure (HR 0.65, 95% CI 0.50–0.83) while the risk of treatment failure due to adverse effects did not differ between the two groups. The results of SANAD II provide evidence that valproate is equally well tolerated and is more effective than levetiracetam in the management of patients with IGEs. Overall, the data indicate that valproate is the most effective drug in patients with IGEs.

With the availability of perampanel, brivaracetam, and lacosamide, few studies have reported the efficacy of these drugs as add-on therapy in patients with IGEs who are not controlled with other drugs. In a double-blind study of 162 patients, perampanel was found to be superior to placebo in reducing the frequency of GTCS over a period of 14 weeks. Similarly, in a real-world open-label study of 149 patients with IGEs not controlled with initial therapy, the 1-year seizure freedom rate with perampanel was 59% while the retention rate was 83%. Similar results were obtained with brivaracetam in a study of 39 patients with IGEs not controlled with other drugs. In an open-label study of 49 patients with IGEs, lacosamide was well tolerated and did not lead to worsening of absence or myoclonic seizures. Overall data with these newer ASMs indicate their efficacy as add-on therapy in patients with IGEs and their potential of use in patients with resistant IGEs. However, these drugs have still not been established as initial monotherapy and further evidence of their effectiveness as compared to established drugs is awaited.

ASMs in childhood absence epilepsy

The only truly double-blind randomized controlled trial in patients with IGEs has studied the efficacy of valproate, lamotrigine, and ethosuximide in patients with CAE. In this study, 453 children with newly diagnosed CAE were randomly assigned to treatment with ethosuximide (156), lamotrigine (149), or valproate (148). At 16 weeks, the freedom-from-failure rate was similar for ethosuximide and valproate (53% and 58%) which was higher than lamotrigine (29%). Rates of adverse events leading to treatment discontinuation were similar in the three groups. However, valproate was associated with higher rates of attention deficit than ethosuximide (49% vs. 33%). A 12-month extension of the trial demonstrated that valproate was associated with higher rates of weight gain, drug discontinuation, and attention deficits. This indicates that ethosuximide should be considered as first choice for CAE when
a patient has absence seizures only.[28] However, ethosuximide is not effective against other seizure types including GTCS and hence valproate should be the first choice drug in such patients with CAE and GTCS. Oxcarbazepine, carbamazepine, phenytoin, tiagabine, and vigabatrin may worsen absence seizures or cause absence status epilepticus and should be avoided in children with CAE [Table 2].[11‑13]

**ASMs in juvenile absence epilepsy**

Being less common as compared to other types of IGEs and with clinical features often overlapping with CAE or JME, there are no studies that evaluated the efficacy of ASMs in patients with isolated JAE. The majority of the trials have included patients with CAE and JAE within the broad group of IGEs. Few studies involving a small number of patients have shown the efficacy of levetiracetam for the control of absence seizures. A small randomized double-blind trial involving 59 patients with newly diagnosed CAE or JAE showed that the seizure freedom rate at two weeks was higher with levetiracetam than placebo (23.7% vs. 4.8%, respectively; \( P = 0.08 \)).[29] In an open-label extension of this trial, 17 of 59 (28%) patients remained seizure free with levetiracetam. Thirty-four patients became seizure free with other ASMs such as valproate (\( n = 27 \)), ethosuximide (\( n = 6 \)), and the combination of valproate and ethosuximide. This along with other observational studies has suggested a moderate efficacy of levetiracetam in the control of absence seizures.[29,30] The majority of the patients with JAE have associated generalized seizures and hence ethosuximide is not a useful drug in this group of patients. A small study involving 13 patients with refractory JAE has reported the efficacy of zonisamide in controlling absence seizures. Of the 13 patients, 5 (38%) patients became seizure free while others had more than 50% reduction in the frequency of absence seizures.[31]

**ASMs in juvenile myoclonic epilepsy**

Valproate was established as an effective drug in patients with JME through many observational studies from the early 1990s onward with a response rate varying from 50% to 80%.[32,33] Subsequently few randomized trials have reported the efficacy of levetiracetam in patients with uncontrolled JME. In a 12-week randomized controlled trial involving 120 patients with previously uncontrolled JME, Noachtar and colleagues reported a better efficacy of levetiracetam as compared to placebo (58.3% vs. 23.3%).[34] Subsequently, few observational studies have reported the efficacy of levetiracetam monotherapy in patients with newly diagnosed JME.[35] Few small unblinded randomized trials and observational studies have also suggested the efficacy of topiramate and zonisamide in patients with JME.[36,37] Phenobarbital was shown to control seizures in 80% of patients with JME in the original descriptions of Janz.[38] Few observational data from India also indicate the efficacy of clobazam in patients with JME.[19]

**IGEs in Women of Reproductive Age Group**

The available data and the clinical experience indicate that valproate is the most effective drug in patients with IGEs. However, data from the last 20 years have suggested significant problems associated with valproate use in women of child-bearing age. Valproate has been shown to have the highest teratogenic potential among all the ASMs from pregnancy registries across the world. The reported rates of major congenital malformation (MCM) with valproate monotherapy in three large prospective ASM pregnancy registries vary from 6.7% to 10.3%.[40‑43] Apart from the risk of malformations, valproate use during pregnancy is associated with lower IQ in exposed children and a higher risk of autism spectrum disorders and attention-deficit hyperactivity disorders.[44‑46] In the prospective “Neurodevelopmental Effects of Antiepileptic Drugs” study, the IQ of the children exposed to high-dose valproate was 8–11 points lower as compared to children exposed to other ASMs.[44] A Cochrane review of 22 prospective cohort studies and six registries has confirmed the association of in-utero valproate exposure and poor neurodevelopmental outcomes of children.[45] Apart from the teratogenic potential of valproate, its use has also been shown to be associated with the development of polycystic ovarian disease, weight gain, and hair loss.[47,48] Based on the teratogenic potential of valproate, many regulatory authorities in the United Kingdom, France, and European Union have issued regulatory guidelines restricting valproate use in women of child-bearing age.[49,50] These guidelines have advocated the insertion of a visible reminder of the risks on the outer packaging of valproate medicines, proper counseling to apprise the women of risks associated with valproate use, maintaining a record that patient has been properly counseled regarding the risks of valproate use during pregnancy, and advise to use proper contraception during valproate use. The French National Agency for the Safety of Medicines and Health Products has banned the use of valproate for the treatment of bipolar disorders in women of child-bearing age.[51] The European Union has introduced a risk acknowledgment form for patients and prescribers to confirm that appropriate advice has been given and understood. Although there has been no express ban on the use of valproate for epilepsy in women, guidelines advise its use only when all the other suitable options have been exhausted and no other option is available.

With these data, valproate should be considered as the last option for young women with IGEs. However, the benefits of not using valproate need to be balanced against the probable risk of poor seizure control in certain women with IGEs. Seizure control during pregnancy is as important as the side effects of ASMs. Valproate is the most effective drug in patients with IGEs and many patients can be controlled only with valproate and no other drug. It has been shown that patients not responding to valproate do not respond to any other monotherapy while patients with no response to other ASMs can be controlled with valproate.[14,62] Stopping valproate or switching from valproate to other ASMs before or during pregnancy has been shown to worsen seizure control.[53,54] Patients with higher seizure frequency during pregnancy have a higher risk of stillbirths, premature delivery, and low birth
weight babies. These data suggest that valproate cannot be completely banned in all women and it should be considered in selected patients who are not controlled with other ASMs after exercising all the precautions and discussing and documenting all the risks and benefits with the patients. There is evidence to suggest that teratogenic and neurocognitive side effects of valproate are dose-dependent. Recent observations from the EURAP epilepsy and pregnancy registry showed that the rate of MCMs was 5.6% with dose <700 mg/day, 10.4% with a dose of 700 to <1500 mg/day, and 24.2% with dose ≥1500 mg/day. These rates were significantly higher compared to 2% MCM observed with lamotrigine <300 mg/day. Results from a pregnancy registry in South India also indicate a dose-dependent increased risk of MCM with valproate. Rates of MCM reported from the registry were 3.2% at doses ≤400 mg/day, 10.1% at doses between 400-800 mg/day, and 33.3% at doses higher than 800 mg/day. There is also growing evidence that valproate has a synergistic effect with lamotrigine and low-dose valproate combined with lamotrigine may be an option in selected patients with drug-resistant IGEs.

With the above discussion, certain conclusions can be drawn for the use of valproate in women of reproductive age group. Valproate should be initiated in women of the reproductive age group when other suitable options have been fully explored. The dose of valproate should be kept at the minimum possible and ideally less than 600 mg/day. If required, low-dose valproate can be combined with lamotrigine for a synergistic effect. All such patients should be properly counseled regarding contraception and the risks of valproate use during pregnancy. This should be documented in the risk acknowledgment form and proper informed consent should be obtained. It should be discussed with the patients during follow-up visits at least once a year and documented. If a woman with epilepsy receiving valproate conceives, she should be seen promptly to discuss the treatment options and outcomes. These women should be followed up regularly during pregnancy in close association with an obstetrician.

Problems with ASMs other than Valproate

No ASM is ideal and all are associated with some or the other problems. Hence, the choice of the initial ASM should be individualized depending upon the patient characteristics. Levetiracetam is associated with behavioral issues such as anxiety, depression, and psychotic symptoms in 10–20% of the patients. Hence, levetiracetam should be avoided in patients with preexisting affective or psychotic symptoms. Topiramate and zonisamide can cause significant cognitive adverse effects and are usually avoided as initial monotherapy. However, both these drugs can cause weight reduction and can be considered as a good initial choice in overweight or obese individuals. Lamotrigine is relatively free of cognitive side effects but can lead to an allergic reaction in 2–5% of patients which necessitates very slow titration. Second, blood levels of lamotrigine fall significantly during the second trimester of pregnancy necessitating monitoring of serum lamotrigine levels and increasing the dose of lamotrigine during the second trimester. Brivaracetam and perampanel are newer broad-spectrum ASMs with the potential of good efficacy in patients with IGEs. Brivaracetam is believed to have a lower incidence of behavioral side effects as compared to levetiracetam. Hence, these drugs may be considered as an option in patients with resistance to other ASMs. However, their safety in pregnancy has not been studied. More studies and clinical experience are required before recommending them for routine use in patients with IGEs.

Treatment Resistant IGEs

Drug-resistant epilepsy (DRE) is defined as the failure of adequate trials of two tolerated, appropriately chosen, and used antiepileptic drug schedules (whether as monotherapy or in combination) to achieve sustained seizure freedom. In patients with IGEs, drug resistant has also been defined even with the failure of adequate doses of valproate to achieve seizure freedom. Approximately, 20–30% of the patients with IGEs have drug resistance. In JME, patients with all three seizure types (myoclonus, absences, and GTCS), associated behavior problems, and with EEG showing trains of polyspikes are more likely to have drug resistance.

Valproate remains the most effective drug in patients with IGEs and it has been shown that patients who do not respond to valproate monotherapy also do not respond to any other ASM. Hence, investigators have suggested that valproate resistance may be considered as a biomarker of drug resistance in IGEs. Various drugs have been found to be effective in patients with drug-resistant IGEs when compared with placebo. Valproate, being the most effective drug, should be tried in all patients who have failed to respond to other ASMs. In patients who do not respond to valproate, the only effective combination is valproate with lamotrigine and this combination should be tried in all the patients with difficult to control IGEs. Chances of seizure freedom in patients not responding to a combination of valproate and lamotrigine are remote. Few small series have demonstrated the efficacy of vagus nerve stimulation as palliative therapy in selected patients with drug-resistant IGEs. However, this palliative procedure should be considered in selected patients where all drug trials have been exhausted.

Duration of Therapy in IGEs

All types of IGEs with the notable exception of CAE are considered long-term disorders and require lifelong therapy. Long-term remission occurs in 65–80% of patients with CAE and ASM withdrawal can be attempted in these patients after 2–3 years of seizure freedom. Previous studies have reported that almost 100% of patients with JAE or JME recur on ASM withdrawal. Based on these observations, it is believed that these patients require lifelong treatment. However, in these studies, ASM withdrawal was attempted after 3–4 years of seizure freedom and at a younger age.
Recent long-term studies in patients with JME with follow-up durations ranging from 30 to 45 years have shown that ASM can be withdrawn in one-third of patients.\(^{71}\) ASM withdrawal can be attempted in patients who are older than 40 years, are seizure-free for a minimum of five years, and have normal EEG. Prognosis in patients with GTCA is variable and has not been well studied. Practically, ASM withdrawal can be tried in these patients after 5 years of seizure freedom with a normal EEG.

**TREATMENT APPROACH AND RECOMMENDATIONS**

For practical purposes, the choice of first monotherapy in patients with IGEs is limited to valproate, lamotrigine, and levetiracetam. The above discussion outlines that valproate is the most effective ASM for the control of seizures in patients with IGEs and should remain the drug of the first choice except in certain special situations and populations. However, both lamotrigine and levetiracetam which have lower efficacy than valproate can be equally good options as initial monotherapy in patients with IGEs.\(^{1,2}\) Lamotrigine and levetiracetam are alternative medicines that can be used in selected patients and patients not responding to a combination of valproate and lamotrigine. Various comorbidities in a given patient should be considered before choosing an ASM in the given patient.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guihoto L, et al. ILAE classification of the epilepsies: Position paper of the ILAE commission for classification and terminology. Epilepsia 2017;58:512-21.

2. Mullen SA, Berkovic SF, ILAE Genetics Commission. Genetic generalized epilepsies. Epilepsia 2018;59:1148-53.

3. Hirsch E, French J, Scheffer IE, Zuberi SM, Trinka E, Specchio N,
et al. ILAE definition of the idiopathic generalized epilepsy syndromes: Position statement by the ILAE Task Force on nosology and definitions. Available from: https://www.ilae.org/guidelines-definition-and-classification/proposed-classification-and-definition-of-epilepsy-syndromes/proposed-classification-idiopathic-generalized-epilepsies. [Last accessed on 2021 Oct 31].

4. Panayiotopoulos CP. Syndromes of idiopathic generalized epilepsies not recognized by the International league against epilepsy. Epilepsia 2005;46(Suppl 9):57-66.

5. Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology and the American epilepsy society. Neurology 2018;91:74-81.

6. Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology and the American epilepsy society. Neurology 2018;91:82-90.

7. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54:551-63.

8. Perucca E, Tomson T. Monotherapy trials with the new antiepileptic drugs: Study designs, practical relevance and ethical implications. Epilepsy Res 1999;33:247-62.

9. Bergey GK. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia 2005;46(Suppl 9):161-8.

10. Benbadis SR. The management of idiopathic generalized epilepsies. Acta Neurol Scand 2005;112(Suppl 181):63-7.

11. Perucca E, Gram L, Avanzini G, Duval O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998;39:5-17.

12. Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000;55:1106-9.

13. Somerville ER. Some treatments cause seizure aggravation in the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 2013;84:1138-47.

14. Wilder BJ, Ramsay RE, Murphy JV, Marquardt K, Kälviäinen R. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54:551-63.

15. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010;362:790-9.

16. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: Initial monotherapy outcomes at 12 months. Epilepsia 2013;54:141-55.

17. Karlbom M, Mårtensson J, Svenningsson P, Tergaonkar V, Mavros P, Germain P, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology and the American epilepsy society. Neurology 2018;91:74-81.

18. National Institute for Health and Care Excellence (NICE) Epilepsies: An open-label pilot study with 59-week extension. Epilepsy Res 2017;130:13-20.

19. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010;362:790-9.

20. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: Initial monotherapy outcomes at 12 months. Epilepsia 2013;54:141-55.

21. Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology and the American epilepsy society. Neurology 2018;91:74-81.

22. Perucca E, Tomson T. Monotherapy trials with the new antiepileptic drugs: Study designs, practical relevance and ethical implications. Epilepsy Res 1999;33:247-62.

23. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010;362:790-9.

24. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: Initial monotherapy outcomes at 12 months. Epilepsia 2013;54:141-55.

25. Kessler SK, McGinnis E. A practical guide to treatment of childhood absence epilepsy. Paediatr Drugs 2019;21:15-24.

26. Kottler C, Boniver C, Capovilla G, Cerminara C, Cittero A, Coppola G, et al. A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia 2011;52:802-9.

27. Wilmot J, Bergey GK, Head J, Sedgwick I, Mancuso S, Glauser T. Levetiracetam in idiopathic generalized epilepsy: A randomized controlled trial. Seizure 2007;16:134-41.

28. Drahter F, Wilm J, Bergey G, Glauser T, Sedgwick I, Mancuso S, et al. Levetiracetam in idiopathic generalized epilepsy: A randomized controlled trial. Seizure 2007;16:134-41.

29. Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000;55:1106-9.

30. Somerville ER. Some treatments cause seizure aggravation in idiopathic epilepsies (especially absence epilepsy). Epilepsia 2005;46(Suppl 9):161-8.

31. Wieder BJ, Ramsay RE, Murphy JV, Karas BJ, Marquardt K, Hammond EJ. Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures. Neurology 1988;33:1747-6.

32. Braathen G, Theorell K, Persson A, Rane A. Valproate in the treatment of absence epilepsy in children: A study of dose-response relationships. Epilepsia 1988;29:548-52.

33. Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000;55:1106-9.

34. Fraser C, Wachtel S, Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000;55:1106-9.

35. Stephen LJ, Hirsch E, et al. Consensus on diagnosis and management of JME: From founder’s observations to current trends. Epilepsie Behav 2013;25(3 Suppl 1):S78-90.

36. Penny JK, Dean JC, Riea AR. Juvenile myoclonic epilepsy: Long-term response to therapy. Epilepsia 1989;30(Suppl 4):S19-23.

37. Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schienn-Medelgado J, N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008;70:607-16.

38. Kottler C, Boniver C, Capovilla G, Cerminara C, Cittero A, Coppola G, et al. A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia 2011;52:802-9.

39. Wolf JS, Bergey GK, Head J, Sedgwick I, Mancuso S, Glauser T. Levetiracetam in idiopathic generalized epilepsy: A randomized controlled trial. Seizure 2007;16:134-41.

40. Kottler C, Boniver C, Capovilla G, Cerminara C, Cittero A, Coppola G, et al. A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia 2011;52:802-9.

41. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sables A, et al. Dose-dependent risk of malformations with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology 2013;10:609-17.

42. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sables A, et al. Comparative risk of major congenital malformations with eight...
different antiepileptic drugs: A prospective cohort study of the EURAP registry. Lancet Neurol 2018;17:530-8.
43. Campbell E, Kennedy F, Russell A, Smithson WH, Parsons L, Morrison PJ, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: Updated results from the UK and Ireland epilepsy and pregnancy registers. J Neurol Neurosurg Psychiatry 2014;85:1029-34.
44. Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): A prospective observational study. Lancet Neurol 2013;12:244-52.
45. Bromley R, Weston J, Adah N, Greenhalgh J, Sanniti A, McKay AI, et al. Treatment for epilepsy in pregnancy: Neurodevelopmental outcomes in the child. Cochrane Database Syst Rev 2014;2014:CD010236.
46. Christensen J, Gronborg TK, Sørensen MJ, Schendel D, Parner ET, Pedersen LH, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013;309:1696-703.
47. Sharpe C, Wolson T, Trauner DA. Weight gain in children treated with valproate. J Child Neurol 2009;24:338-41.
48. Harden CL. Polycystic ovaries and polycystic ovary syndrome in epilepsy: Evidence for neurogonadal disease. Epilepsy Curr 2005;5:142-6.
49. European Medicine Agency. New measures to avoid valproate exposure in pregnancy endorsed. 23 March 2018. EMA/145600/2018. Available from: https://www.ema.europa.eu/en/documents/press-release/new-measures-avoid-valproate-exposure-pregnancy-endorsed_en.pdf. [Last accessed on 2020 Nov 10].
50. Sen A, Nashef L. New regulations to cut valproate-exposed pregnancies. Lancet 2018;392:458-60.
51. Casassus B. France bans sodium valproate use in case of pregnancy. Lancet 2017;390:27.
52. Gesche J, Khanesvari M, Solberg C, Beier CP. Resistance to valproic acid as predictor of treatment resistance in genetic generalized epilepsies. Epilepsia 2017;58:e64-9.
53. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP. Epilepsia 2016;57:e173-7.
54. Cerullifredi E, Morano A, Cocchi E, Casciato S, Fanella M, Albini M, et al. Doing without valproate in women of childbearing potential with idiopathic generalized epilepsy: Implications on seizure outcome. Epilepsia 2020;61:107-14.
55. Chen YH, Chiou HY, Lin HC, Lin HL. Affect of seizures during gestation on pregnancy outcomes in women with epilepsy. Arch Neurol 2009;66:979-84.
56. Rauchenzauner M, Ehrensberger M, Prieschl M, Kapelari K, Bergmann M, Walser G, et al. Generalized tonic-clonic seizures and antiepileptic drugs during pregnancy—A matter of importance for the baby? J Neurol 2013;260:484-8.
57. Thomas RH. Valproate: Life-saving, life-changing. Clin Med (Lond) 2018;18(Suppl 2):s1-8.
58. Thomas SV, Jose M, Divakaran S, Sankara Sarma P. Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: Results from a pregnancy registry in South India. Epilepsia 2017;58:274-81.
59. Baheti N, Rathore C, Bansal AR, Shah S, Veedu HK, Prakash S, et al. Treatment outcomes in drug resistant juvenile myoclonic epilepsy: Valproate resistance may not be the end of the road. Seizure 2021;92:112-7.
60. Chen B, Choi H, Hirsch LJ, Katz A, Legge A, Bachsbaum R, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav 2017;76:24-31.
61. Wandschneider B, Burdett J, Townsend L, Hill A, Thompson PJ, Duncan JS, et al. Effect of topiramate and zonisamide on fMRI cognitive networks. Neurology 2017;88:1165-71.
62. Park SP, Hwang YH, Lee HW, Suh CK, Kwon SH, Lee BI. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav 2008;12:102-8.
63. Pennell PB, Peng L, Newport DJ, Ritchie JC, Koganti A, Holley DK, et al. Lamotrigine in pregnancy: Clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008;70:2130-6.
64. Sanon NT, Gagné J, Wolf DC, Aboulamer S, Bosoi CM, Simard A, et al. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model. Epilepsy Behav 2018;79:117-25.
65. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia 2010;51:1069-7.
66. Gomez-Ibañez A, McLachlan RS, Mirsattari SM, Diosy DC, Burneo JG. Prognostic factors in patients with refractory idiopathic generalized epilepsy. Epilepsy Res 2017;130:69-73.
67. Colleran N, Connor TO, Brien JJ. Anti epileptic drug trials for patients with drug resistant idiopathic generalised epilepsy. A meta-analysis. Seizure 2017;51:145-56.
68. Kostov H, Larsson R, Rost G. Is vagus nerve stimulation a treatment option for patients with drug-resistant idiopathic generalized epilepsy? Acta Neurol Scand 2007;118:55-8.
69. Wirrell EC, Camfield CS, Camfield PR, Gordon KE, Dooley JM. Long-term prognosis of typical childhood absence epilepsy: Remission or progression to juvenile myoclonic epilepsy. Neurology 1996;47:912-8.
70. Pavlović M, Jović N, Pekmezović T. Antiepileptic drugs withdrawal in patients with idiopathic generalized epilepsy. Seizure 2011;20:520-8.
71. Camfield CS, Camfield PR. Juvenile myoclonic epilepsy 25 years after seizure onset: A population-based study. Neurology 2009;73:1041-5.